These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

700 related items for PubMed ID: 25557757

  • 21. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
    Kagan R.
    J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Management of Menopausal Symptoms: A Review.
    Crandall CJ, Mehta JM, Manson JE.
    JAMA; 2023 Feb 07; 329(5):405-420. PubMed ID: 36749328
    [Abstract] [Full Text] [Related]

  • 24. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.
    Tella SH, Gallagher JC.
    Expert Opin Pharmacother; 2013 Dec 07; 14(17):2407-20. PubMed ID: 24093499
    [Abstract] [Full Text] [Related]

  • 25. What do TSECs provide in the menopausal hormone therapy?
    Llaneza P, Calaf J, Jurado AR, Mendoza N, Otero B, Quereda F, Sánchez-Borrego R, Lubian D.
    Gynecol Endocrinol; 2018 Oct 07; 34(10):826-832. PubMed ID: 29790381
    [Abstract] [Full Text] [Related]

  • 26. Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.
    Stovall DW, Tanner-Kurtz K, Pinkerton JV.
    Drugs; 2011 Sep 10; 71(13):1649-57. PubMed ID: 21902289
    [Abstract] [Full Text] [Related]

  • 27. Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes.
    Smith CL, Santen RJ, Komm B, Mirkin S.
    Breast Cancer Res; 2014 Jun 18; 16(3):212. PubMed ID: 25928299
    [Abstract] [Full Text] [Related]

  • 28. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H.
    Climacteric; 2003 May 18; 6 Suppl 1():11-36. PubMed ID: 12945798
    [Abstract] [Full Text] [Related]

  • 29. Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture.
    Rossini M, Lello S, Sblendorio I, Viapiana O, Fracassi E, Adami S, Gatti D.
    Drug Des Devel Ther; 2013 May 18; 7():601-10. PubMed ID: 23901263
    [Abstract] [Full Text] [Related]

  • 30. MF101: a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms.
    Leitman DC, Christians U.
    Expert Opin Investig Drugs; 2012 Jul 18; 21(7):1031-42. PubMed ID: 22616988
    [Abstract] [Full Text] [Related]

  • 31. Selective estrogen receptor modulators in clinical practice: a safety overview.
    Ellis AJ, Hendrick VM, Williams R, Komm BS.
    Expert Opin Drug Saf; 2015 Jun 18; 14(6):921-34. PubMed ID: 25936229
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.
    Pinkerton JV, Komm BS, Mirkin S.
    Climacteric; 2013 Dec 18; 16(6):618-28. PubMed ID: 23805785
    [Abstract] [Full Text] [Related]

  • 34. Hormone replacement therapy in postmenopausal women.
    Prelevic GM, Kocjan T, Markou A.
    Minerva Endocrinol; 2005 Mar 18; 30(1):27-36. PubMed ID: 15877011
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
    Constantine GD, Revicki DA, Kagan R, Simon JA, Graham S, Bernick B, Mirkin S.
    Menopause; 2019 May 18; 26(5):513-519. PubMed ID: 30516713
    [Abstract] [Full Text] [Related]

  • 36. A new approach to menopausal therapy: the tissue selective estrogen complex.
    Komm BS.
    Reprod Sci; 2008 Dec 18; 15(10):984-92. PubMed ID: 19088368
    [Abstract] [Full Text] [Related]

  • 37. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
    Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S.
    Maturitas; 2014 Jul 18; 78(3):212-8. PubMed ID: 24837362
    [Abstract] [Full Text] [Related]

  • 38. Differential effects of menopausal therapies on the endometrium.
    Mirkin S, Archer DF, Taylor HS, Pickar JH, Komm BS.
    Menopause; 2014 Aug 18; 21(8):899-908. PubMed ID: 24518153
    [Abstract] [Full Text] [Related]

  • 39. What happened to WHI: menopausal hormonal therapy in 2012.
    Hansen KA, Eyster KM.
    Clin Obstet Gynecol; 2012 Sep 18; 55(3):706-12. PubMed ID: 22828102
    [Abstract] [Full Text] [Related]

  • 40. Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen.
    Simon JA, Snabes MC.
    Expert Opin Investig Drugs; 2007 Dec 18; 16(12):2005-20. PubMed ID: 18042008
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.